Evaluation of nonmotor symptoms in myasthenia gravis patients
Open Access
- 18 February 2025
- journal article
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 127-139
Abstract
Background/aim: Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. In this study, we aimed to evaluate non-motor symptoms in myasthenia gravis patients and compare them with disease duration, severity and clinical features.Materials and methods: This prospective study was conducted with thirty-five myasthenia gravis patients and thirty-five healthy volunteers. Total of 35 patients, 17 women and 18 men with mean age of 52.9±13.6 years constituted patient group. Control group consisted of total of 35 participants, 23 women and 12 men with mean age of 46.9±12.2 years. Patient group was applied scales of MG Foundation of America clinical classification, MG Composite and Turkish version of MG Quality of Life 15. For non-motor functions, both in patients and controls; we used the inquiry questionnaires evaluating symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell and taste. Results: Results revealed prevalent and diverse non-motor symptoms in MG patients. Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon in patient group was significantly (p<0.05) lower than control group. Rate of impaired MoCA degree, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, rate of poor PSQI in patient group was significantly (p<0.05) higher than control group.Conclusion: In conclusion, our study emphasizes importance of recognizing and managing non-motor symptoms in MG patients, advocating for multidisciplinary approach to care that addresses both motor and non-motor manifestations. By expanding our understanding of MG's systemic impact and exploring new treatment modalities, we can improve lives of those living with this complex autoimmune disorder. Further research is needed to elucidate pathogenic mechanisms underlying these non-motor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.Keywords
This publication has 46 references indexed in Scilit:
- Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia GravisArchives of Neurology, 2012
- Headache Associated with Myasthenia Gravis: The Impact of Mild Ocular SymptomsAutoimmune Diseases, 2011
- Myasthenia and related disorders of the neuromuscular junctionJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe Lancet Neurology, 2009
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- Self-reported Pain Affects Quality of Life in Myasthenia GravisJournal of Clinical Neuromuscular Disease, 2006
- Irreversible cochlear damage in myasthenia gravis - otoacoustic emission analysisActa Neurologica Scandinavica, 2006
- Myasthenia gravisThe Lancet, 2001
- [Systemic manifestations of myasthenia gravis and its putative pathogenesis].1997
- Evaluation of olfactory dysfunction in the connecticut chemosensory clinical research centerThe Laryngoscope, 1988